This National Institutes of Health grant is designed to provide proof-of-principle for novel immunotherapeutic strategies aimed at Alzheimer Disease and Alzheimer Related Dementias (AD/ADRD). This grant is for the purpose of exploring whether Chimeric Antigen Receptor (CAR) immune cell approaches, which have shown significant promise in cancer immunotherapy, can be effectively customized and applied as innovative treatments for AD/ADRD. The funding utilizes the R61/R33 Exploratory/Developmental Phased Award activity code, structured to support research through distinct stages. The R61 phase offers up to two years of support for initial developmental activities and critical proof-of-concept studies. Subsequently, the R33 phase provides up to three years of support for expanded research and more comprehensive development efforts, building upon the successes of the R61. The ultimate goal is to pioneer groundbreaking immunotherapies to combat these debilitating neurodegenerative diseases.
Opportunity ID: 349970
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AG-24-046 |
| Funding Opportunity Title: | Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 23, 2023 |
| Last Updated Date: | Aug 23, 2023 |
| Original Closing Date for Applications: | Feb 07, 2024 |
| Current Closing Date for Applications: | Feb 07, 2024 |
| Archive Date: | Mar 14, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments For profit organizations other than small businesses Native American tribal governments (Federally recognized) City or township governments County governments Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public housing authorities/Indian housing authorities Special district governments Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Notice of Funding Opportunity (NOFO) aims toprovide a proof-of-principle for a novel strategy for Alzheimer Disease and Alzheimer Related Dementias (AD/ADRD) immunotherapies. Specifically, the goal is to examine if a novel immunotherapeutic approach in cancer immunotherapy with Chimeric Antigen Receptor (CAR) immune cellscould be customized as treatments for AD/ADRD. This NOFO utilizes the R61/R33Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-046.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 349970 Full Announcement-RFA-AG-24-046 -> RFA-AG-24-046-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00282965 | Jan 07, 2024 | Feb 07, 2024 | View |
Package 1
Mandatory forms
349970 RR_SF424_5_0-5.0.pdf
349970 PHS398_CoverPageSupplement_5_0-5.0.pdf
349970 RR_OtherProjectInfo_1_4-1.4.pdf
349970 PerformanceSite_4_0-4.0.pdf
349970 RR_KeyPersonExpanded_4_0-4.0.pdf
349970 RR_Budget10_3_0-3.0.pdf
349970 PHS398_ResearchPlan_5_0-5.0.pdf
349970 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
349970 RR_SubawardBudget10_30_3_0-3.0.pdf
349970 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
